content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Athersys, Inc. (ATHX)

2.03
-0.06
(-2.87%)
Sep 11, 4:00PM EDT
content_middle

Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.

Previous Close: 
2.09
Open: 
2.11
Bid: 
1.95
Ask: 
2.03
1yr Target Price: 
7.75
Day's Range: 
1.89 - 2.11
52wk Range: 
1.02 - 2.30
Volume: 
1362784
Average Daily Volume: 
758703
Market Capitalization: 
231.24M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
113911000M
content_right

Pages